• Users Online: 186
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 17  |  Issue : 1  |  Page : 35-47

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years

Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Correspondence Address:
Abd El-Magid M Tag El-Din
1st District Omar Zaafan Street, Building 13, Flat 602, Nasr City, Cairo 11765
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/AZMJ.AZMJ_115_18

Rights and Permissions

Background Diabetic macular edema (DME) is a common cause of blindness and visual impairment in diabetic patients, which can affect the quality of life. Aflibercept and ranibizumab are used as intravitreal anti-vascular endothelial growth factor injections; both of them have a relatively safe effective treatment of DME. Aim of the work To compare the effect of aflibercept and ranibizumab in the management of DME. Patients and methods A prospective invasive and nonrandomized study, including 20 eyes in 20 patients, more than 40 years old, was conducted in Al-Azhar Faculty of Medicine, Cairo, with three times injections 1 month apart. Eyes were divided into two groups: group A included 10 patients who received ranibizumab 0.5 mg (0.05 ml of 10 mg/ml solution) as an intravitreal injection, and group B included 10 patients who received aflibercept 2 mg (0.05 ml of 40 mg/ml solution) as an intravitreal injection. Follow-up period was 4 months. Results A statistically significant improvement of best-corrected visual acuity (BCVA) and central macular thickness with ranibizumab was reported over the follow-up period. There was also a statistically significant improvement of BCVA, central macular thickness, and intraocular pressure over the follow-up visits with aflibercept. Ranibizumab was more effective in BCVA correction and in the reduction of central macular thickness than aflibercept. Conclusion Both ranibizumab and aflibercept are effective in improving the BCVA and in the reduction of central macular thickness. Ranibizumab is more effective for BCVA correction and in the reduction of central macular thickness than aflibercept Recommendations Further studies are needed to confirm the effect of ranibizumab and aflibercept intravitreal injection on the central macular thickness and intraocular pressure.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded92    
    Comments [Add]    

Recommend this journal